RDD Blog » 2010 » May

R&D Directions Insider

Archive for May, 2010

NIH wants tighter oversight of research money trail

Friday, May 28th, 2010

In our May cover story on patient recruitment, we talk a bit about the issue of transparency and how the federal government and industry are seemingly taking steps to better address public trust concerns in the research process. The latest example is a new conflict of interest rule being proposed by ...

Posted in Uncategorized | No Comments »

Why FBI was at BIO, and why scientists should wake up

Thursday, May 13th, 2010

In the far back of the exhibit hall in McCormick Place at BIO 2010, in a quiet corner, two well-dressed men were sitting at an understated booth. But they were not with any pharmaceutical or biotech company, or a law firm, or with any of the state, regional, or national ...

Posted in Uncategorized | 2 Comments »

Tool addresses biologic registration limits

Friday, May 7th, 2010

Scientific software company Accelrys Inc. recently unveiled the worldâ€™s first multi-entity, production-ready biologics registration system. Developed from a three-year collaboration withÂ drugmakers including Abbott and Merck & Co., the data tool is designed to helpÂ companies overcome the historically difficult IT challenges associated with registering and defining complex biological materials. Accelrys' database ...

Posted in antibodies, drug discovery | No Comments »

Some thoughts from BIO 2010 (or how not to handle media)

Thursday, May 6th, 2010

It's been a hectic two and a half days in Chicago at BIO 2010, the Biotechnology Industry Organization's annual convention. I've interviewed people from Scottish Enterprise and Berlin Partner about their efforts to attract life sciences investment in their regions; sat down with experts from Deloitte and Ernst & Young ...

Posted in Uncategorized | 1 Comment »

©2012 UBM Canon